259214-56-7Relevant articles and documents
CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF
-
Paragraph 00519, (2017/09/27)
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease
Jiang, Yutong,Andrews, Steven W.,Condroski, Kevin R.,Buckman, Brad,Serebryany, Vlad,Wenglowsky, Steve,Kennedy, April L.,Madduru, Machender R.,Wang, Bin,Lyon, Michael,Doherty, George A.,Woodard, Benjamin T.,Lemieux, Christine,Do, Mary Geck,Zhang, Hailong,Ballard, Joshua,Vigers, Guy,Brandhuber, Barbra J.,Stengel, Peter,Josey, John A.,Beigelman, Leonid,Blatt, Lawrence,Seiwert, Scott D.
supporting information, p. 1753 - 1769 (2014/04/03)
HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate im
Hepatitis C Virus Inhibitors
-
Page/Page column, (2013/05/21)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.